The megaround rebound: Private biotechs rack up $100M+ financings
Big money is back.
Over the past 12 weeks, biotech startups have raised $100 million-plus megarounds from venture capitalists at a pace that could approach the market’s peak three years ago.
This week alone, three startups announced major new financings. Engrail, a neuroscience company in Phase 2, took in $157 million. Two preclinical biotechs, T cell engager player Clasp and in vivo CAR-T startup Capstan, landed $150 million and $175 million, respectively.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
